Cure My Disease
Don't miss your cure!
Clinical trials sponsored by Modulation Therapeutics, Inc., explained in plain language.
This early-phase trial tests a radioactive drug called 225Ac-MTI-201 in 16 people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The main goal is to find the highest safe dose and understand side effects. Participants receive a singl…
Phase: PHASE1 • Sponsor: Modulation Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC